Cefuroxime sodium/sulbactam sodium intravenous - Shenzhen Salubris Pharmaceuticals

Drug Profile

Cefuroxime sodium/sulbactam sodium intravenous - Shenzhen Salubris Pharmaceuticals

Latest Information Update: 25 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shenzhen Salubris Pharmaceuticals
  • Class Antibacterials; Cephalosporins; Penicillins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Respiratory tract infections; Urinary tract infections

Most Recent Events

  • 24 Nov 2015 Clinical trials in Respiratory tract infections in China (IV)
  • 24 Nov 2015 Clinical trials in Urinary tract infections in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top